These two companies could move in different directions over the medium term.

Recursion Pharmaceuticals RXRX, a TechBio company, is expected to beat expectations when it reports third-quarter 2026 ...

In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $4.03, marking a -4.95% move from the previous day. The stock's change was less than the S&P 500's daily loss of 1.82%.

A formalization of Kleene's second recursion theorem in the untyped lambda calculus yields a working Quine, with the proof carried out in the Rocq proof assistant. The approach highlights how the ...

Webinar will include earnings updates and REC-4881 data as well as KOL and patient panels, presented live from CGA-IGC on Tuesday, November 3, ...

Key TakeawaysAbsci fell 8% today as AI drug discovery peers Schrödinger and Recursion slid in a Nasdaq sell-off. These stocks trade together on sentiment, so the drop says little about Absci’s ...

Key TakeawaysAbsci rose 12% today, Schrödinger 11% and Recursion 9%, and no company news explains any of the three moves. Schrödinger’s rally has the most business behind it, and Absci’s rally is ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Recursion Pharmaceuticals Inc. stocks have been trading up by 7.04 percent following upbeat coverage of its AI-driven drug discovery advancements. Key Takeaways Traders Are Watching A $200M follow-on ...

In October 2026, EDO|imurah became completely obsessed with Competitive Brawl.I've been having so much fun with MTG Arena ...

A unique Mono-Black Devotion deck put up a strong result in a big Pioneer event, showcasing the power of Baron Helmut Zemo.

Recursion Pharmaceuticals (RXRX) possesses the right combination of the two key ingredients for a likely earnings beat in its ...